Title:
ANTI-CD22 FULLY HUMAN ANTIBODY OR ANTIGEN BINDING FRAGMENT THEREOF, PREPARATION METHOD THEREFOR, AND USE THEREOF
Document Type and Number:
WIPO Patent Application WO/2022/262783
Kind Code:
A1
Abstract:
An anti-CD22 fully human antibody or an antigen binding fragment thereof, a preparation method therefor and a use thereof. The anti-CD22 antibody or the antigen binding fragment thereof is screened from a fully human phage display library, and is formed by means of a flexible linker peptide linking a heavy chain variable region and a light chain variable region. Framework region sequences and complementarity determining region (CDR) sequences of the heavy chain variable region and the light chain variable region are derived from humans.
Inventors:
LONG FEI (CN)
DIMITROV DIMITER S (US)
URA MARCIN (US)
PETERSON ERIC (US)
MELLORS JOHN (US)
DIMITROV DIMITER S (US)
URA MARCIN (US)
PETERSON ERIC (US)
MELLORS JOHN (US)
Application Number:
PCT/CN2022/099016
Publication Date:
December 22, 2022
Filing Date:
June 15, 2022
Export Citation:
Assignee:
XIAN YUFAN BIOTECHNOLOGIES CO LTD (CN)
ABOUND BIO INC (US)
ABOUND BIO INC (US)
International Classes:
C07K16/28; C12N15/13; C12P21/08
Domestic Patent References:
| WO1994027638A1 | 1994-12-08 |
Foreign References:
| CN103588882A | 2014-02-19 | |||
| CA2484420A1 | 2003-11-13 | |||
| CN109678965A | 2019-04-26 | |||
| CN1662558A | 2005-08-31 | |||
| CN109836495A | 2019-06-04 |
Attorney, Agent or Firm:
BEIJING LINKTEC IP LAW FIRM (SPECIAL GENERAL PARTNERSHIP) (CN)
Download PDF:
Previous Patent: GLUTARIMIDE-SUBSTITUTED ISOXAZOLE FUSED RING COMPOUND, AND APPLICATION THEREOF
Next Patent: IDH MUTANT INHIBITOR AND USE THEREOF
Next Patent: IDH MUTANT INHIBITOR AND USE THEREOF